PPARgamma Modulates CD4⁺ T-Cell Differentiation and Allergic Inflammation in Allergic Rhinitis: A Potential...

Area of Science:

• Immunology
• Allergy Research
• Molecular Medicine

Background:

• Allergic rhinitis (AR) prevalence is rising, with CD4+ T-cell subsets like regulatory T cells (Tregs) and T helper (TH)1, TH2, and TH17 cells implicated in its pathogenesis.
• Peroxisome proliferator-activated receptor gamma (PPARgamma) is increasingly recognized for its role in immune regulation, making it a potential therapeutic target for immune-mediated diseases.

Purpose of the Study:

• To investigate the impact of PPARgamma pathway modulation on CD4+ T-cell subset balance in the context of allergic rhinitis.
• To explore the therapeutic potential of targeting the PPARgamma-CD4+ T-cell axis for effective AR management.

Main Methods:

• Utilized PPARgamma-deficient mice (PPARgamma(f/f)Lyz2-Cre) and an ovalbumin (OVA)-induced AR mouse model.
• Assessed allergic symptoms, splenic Tregs, and nasal eosinophils in PPARgamma-deficient mice.
• Examined the effect of a PPARgamma agonist on naive CD4+ T-cell polarization.

Main Results:

• PPARgamma deficiency exacerbated allergic symptoms, reduced splenic Tregs, and increased nasal eosinophil infiltration.
• PPARgamma agonist treatment enhanced Treg differentiation from naive CD4+ T cells.
• PPARgamma agonist treatment suppressed the differentiation of TH1, TH2, and TH17 cells.

Conclusions:

• PPARgamma plays a critical role in regulating TH-cell subsets, particularly in the context of allergic rhinitis.
• PPARgamma agonists show promise as a therapeutic strategy for AR by promoting Treg development and inhibiting pathogenic TH-cell responses.